The Most Predictive Red Flags for Suspecting Cardiac Amyloidosis in Patients with Heart Failure with Preserved Ejection Fraction. 2024

Halit Emre Yalvaç, and Selda Murat, and İlknur Ak Sivrikoz, and Hava Üsküdar Teke, and Oğuz Çilingir, and Ertuğrul Çolak, and Yüksel Çavuşoğlu
Department of Cardiology, Eskişehir City Hospital, Eskişehir, Türkiye.

OBJECTIVE Cardiac amyloidosis (CA) is a cardiomyopathy characterized by amyloid infiltration in the myocardium. Transthyretin cardiac amyloidosis (TTR-CA), commonly presenting as heart failure with preserved ejection fraction (HFpEF), was the focus of our study, which aimed to identify red flags that heighten suspicion of CA in HFpEF patients. METHODS We prospectively included patients diagnosed with HFpEF. All patients were assessed for TTR-CA red flag features, cardiac and extra-cardiac, as outlined in the 'Diagnosis and Treatment of Cardiac Amyloidosis: A Position Statement of the European Society of Cardiology.' Technetium-99m pyrophosphate (99mTc-PYP) cardiac scintigraphy was performed in 167 HFpEF patients suspected of having TTR-CA. Patients testing positive and negative for TTR-CA were compared based on these red flag features. RESULTS Out of 167 HFpEF patients, 19 (11.3%) were diagnosed with TTR-CA. In the TTR-CA group, 17 (89.5%) patients were 65 years or older. The presence of three or more red flags differentiated the TTR-CA positive and negative groups (P = 0.040). Features such as low voltage and pseudo infarct patterns were more prevalent in the TTR-CA group (P < 0.001 and P < 0.048, respectively). Left ventricular global longitudinal strain (LV-GLS) was lower in the TTR-CA positive group (P < 0.001). Multivariate analysis identified four variables-older age, pseudo infarct pattern, low/decreased QRS voltage, and LV-GLS-as strong, independent predictors of TTR-CA, with significant odds ratios (ORs) of 7.8, 6.8, 16.9, and 1.2, respectively. CONCLUSIONS In this study, TTR-CA etiology occurs in approximately one in every ten HFpEF patients. The presence of three or more red flags increases the likelihood of TTR-CA. Older age, pseudo infarct pattern, low/decreased QRS voltage, and reduced LV-GLS are the most significant red flags indicating TTR-CA in HFpEF patients.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009202 Cardiomyopathies A group of diseases in which the dominant feature is the involvement of the CARDIAC MUSCLE itself. Cardiomyopathies are classified according to their predominant pathophysiological features (DILATED CARDIOMYOPATHY; HYPERTROPHIC CARDIOMYOPATHY; RESTRICTIVE CARDIOMYOPATHY) or their etiological/pathological factors (CARDIOMYOPATHY, ALCOHOLIC; ENDOCARDIAL FIBROELASTOSIS). Myocardial Disease,Myocardial Diseases,Myocardial Diseases, Primary,Myocardial Diseases, Secondary,Myocardiopathies,Primary Myocardial Disease,Cardiomyopathies, Primary,Cardiomyopathies, Secondary,Primary Myocardial Diseases,Secondary Myocardial Diseases,Cardiomyopathy,Cardiomyopathy, Primary,Cardiomyopathy, Secondary,Disease, Myocardial,Disease, Primary Myocardial,Disease, Secondary Myocardial,Diseases, Myocardial,Diseases, Primary Myocardial,Diseases, Secondary Myocardial,Myocardial Disease, Primary,Myocardial Disease, Secondary,Myocardiopathy,Primary Cardiomyopathies,Primary Cardiomyopathy,Secondary Cardiomyopathies,Secondary Cardiomyopathy,Secondary Myocardial Disease
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D005260 Female Females
D006333 Heart Failure A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION. Cardiac Failure,Heart Decompensation,Congestive Heart Failure,Heart Failure, Congestive,Heart Failure, Left-Sided,Heart Failure, Right-Sided,Left-Sided Heart Failure,Myocardial Failure,Right-Sided Heart Failure,Decompensation, Heart,Heart Failure, Left Sided,Heart Failure, Right Sided,Left Sided Heart Failure,Right Sided Heart Failure
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000686 Amyloidosis A group of sporadic, familial and/or inherited, degenerative, and infectious disease processes, linked by the common theme of abnormal protein folding and deposition of AMYLOID. As the amyloid deposits enlarge they displace normal tissue structures, causing disruption of function. Various signs and symptoms depend on the location and size of the deposits. Amyloidoses
D013318 Stroke Volume The amount of BLOOD pumped out of the HEART per beat, not to be confused with cardiac output (volume/time). It is calculated as the difference between the end-diastolic volume and the end-systolic volume. Ventricular Ejection Fraction,Ventricular End-Diastolic Volume,Ventricular End-Systolic Volume,Ejection Fraction, Ventricular,Ejection Fractions, Ventricular,End-Diastolic Volume, Ventricular,End-Diastolic Volumes, Ventricular,End-Systolic Volume, Ventricular,End-Systolic Volumes, Ventricular,Fraction, Ventricular Ejection,Fractions, Ventricular Ejection,Stroke Volumes,Ventricular Ejection Fractions,Ventricular End Diastolic Volume,Ventricular End Systolic Volume,Ventricular End-Diastolic Volumes,Ventricular End-Systolic Volumes,Volume, Stroke,Volume, Ventricular End-Diastolic,Volume, Ventricular End-Systolic,Volumes, Stroke,Volumes, Ventricular End-Diastolic,Volumes, Ventricular End-Systolic

Related Publications

Halit Emre Yalvaç, and Selda Murat, and İlknur Ak Sivrikoz, and Hava Üsküdar Teke, and Oğuz Çilingir, and Ertuğrul Çolak, and Yüksel Çavuşoğlu
December 2022, European journal of heart failure,
Halit Emre Yalvaç, and Selda Murat, and İlknur Ak Sivrikoz, and Hava Üsküdar Teke, and Oğuz Çilingir, and Ertuğrul Çolak, and Yüksel Çavuşoğlu
January 2019, Amyloid : the international journal of experimental and clinical investigation : the official journal of the International Society of Amyloidosis,
Halit Emre Yalvaç, and Selda Murat, and İlknur Ak Sivrikoz, and Hava Üsküdar Teke, and Oğuz Çilingir, and Ertuğrul Çolak, and Yüksel Çavuşoğlu
July 2017, Arquivos brasileiros de cardiologia,
Halit Emre Yalvaç, and Selda Murat, and İlknur Ak Sivrikoz, and Hava Üsküdar Teke, and Oğuz Çilingir, and Ertuğrul Çolak, and Yüksel Çavuşoğlu
August 2017, JACC. Heart failure,
Halit Emre Yalvaç, and Selda Murat, and İlknur Ak Sivrikoz, and Hava Üsküdar Teke, and Oğuz Çilingir, and Ertuğrul Çolak, and Yüksel Çavuşoğlu
March 2020, Cardiac failure review,
Halit Emre Yalvaç, and Selda Murat, and İlknur Ak Sivrikoz, and Hava Üsküdar Teke, and Oğuz Çilingir, and Ertuğrul Çolak, and Yüksel Çavuşoğlu
October 2012, Journal of cardiac failure,
Halit Emre Yalvaç, and Selda Murat, and İlknur Ak Sivrikoz, and Hava Üsküdar Teke, and Oğuz Çilingir, and Ertuğrul Çolak, and Yüksel Çavuşoğlu
September 2017, Circulation. Cardiovascular imaging,
Halit Emre Yalvaç, and Selda Murat, and İlknur Ak Sivrikoz, and Hava Üsküdar Teke, and Oğuz Çilingir, and Ertuğrul Çolak, and Yüksel Çavuşoğlu
November 2020, Echocardiography (Mount Kisco, N.Y.),
Halit Emre Yalvaç, and Selda Murat, and İlknur Ak Sivrikoz, and Hava Üsküdar Teke, and Oğuz Çilingir, and Ertuğrul Çolak, and Yüksel Çavuşoğlu
January 2021, Trends in cardiovascular medicine,
Halit Emre Yalvaç, and Selda Murat, and İlknur Ak Sivrikoz, and Hava Üsküdar Teke, and Oğuz Çilingir, and Ertuğrul Çolak, and Yüksel Çavuşoğlu
January 2014, Clinical Medicine Insights. Cardiology,
Copied contents to your clipboard!